Coherus Oncology, Inc. — Director's Dealing 2021

Jan 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Coherus BioSciences, Inc. (CHRS)
CIK: 0001512762
Period of Report: 2021-01-25

Reporting Person: Viret Jean-Frederic (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-25	Common Stock	M	40000	$10.05	Acquired	107439	Direct
2021-01-25	Common Stock	S	40000	$20.10	Disposed	67439	Direct
2021-01-25	Common Stock	S	6144	$19.00	Disposed	61295	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-25	Stock Option (Right to Buy)	$10.05	M	40000	Disposed	2028-02-01	Common Stock (40000)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person.

F2: Includes 52,083 restricted stock units.

F3: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.